R&D expense · 2011–2025
Haemonetics R&D expense
$59.8M−4.7% · FY2025
Haemonetics (HAE) reported $59.8M in R&D expense for fiscal 2025, −4.7% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252026-03-28 | $59.8M | −4.7% | Open → |
| FY20242025-03-29 | $62.7M | +15.2% | Open → |
| FY20232024-03-30 | $54.4M | +8.6% | Open → |
| FY20222023-04-01 | $50.1M | +7.1% | Open → |
| FY20212022-04-02 | $46.8M | +42.4% | Open → |
| FY20202021-04-03 | $32.9M | +6.4% | Open → |
| FY20192020-03-28 | $30.9M | −13.5% | Open → |
| FY20182019-03-30 | $35.7M | −9.0% | Open → |
| FY20172018-03-31 | $39.2M | +4.5% | Open → |
| FY20162017-04-01 | $37.6M | −16.5% | Open → |
| FY20152016-04-02 | $45.0M | −17.0% | Open → |
| FY20142015-03-28 | $54.2M | −0.0% | Open → |
| FY20132014-03-29 | $54.2M | +22.1% | Open → |
| FY20122013-03-30 | $44.4M | +20.6% | Open → |
| FY20112012-03-31 | $36.8M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +3.5%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Haemonetics R&D expense |url=https://companiesranked.com/en/company/haemonetics/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Haemonetics R&D expense. CompaniesRanked. https://companiesranked.com/en/company/haemonetics/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-haemonetics-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Haemonetics R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/haemonetics/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000313143-26-000050 · May 20, 2026
{{cite web |title=Haemonetics R&D expense — 10-K (0000313143-26-000050) |url=https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-05-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.